(Q36637666)

15 August 2017

1 reference

title

Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities (English)

1 reference

15 August 2017

3

Hans-Jürgen Möller

1 reference

15 August 2017

Thomas C Baghai

1

1 reference

15 August 2017

Hans-Peter Volz

series ordinal

2

1 reference

15 August 2017

publication date

1 January 2006

1 reference

World Journal of Biological Psychiatry

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

198-222

1 reference

Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Meta-analytical studies on new antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthre

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Rapid reversal of psychotic depression using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

An open label trial of C-1073 (mifepristone) for psychotic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Anxiolytic effects of 3α-hydroxy-5α[β]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The scientific, quasi-scientific and popular literature on the use of St. John's Wort in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Systematic review and guide to selection of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Evidence based review of escitalopram in treating major depressive disorder in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Rhythmic transcription: the molecular basis of circadian melatonin synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The SSRI discontinuation syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Hypericum perforatum--a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Reboxetine: the first selective noradrenaline re-uptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

St. John's wort for depression: a meta-analysis of well-defined clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Efficacy of venlafaxine in depressive illness in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

St John's wort for depression: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Efficacy of escitalopram in patients with severe depression: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Hyperforin in St. John's wort drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Limited efficacy of ketoconazole in treatment-refractory major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Drug treatment of depression in the 1990s. An overview of achievements and future possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The antidepressant efficacy of reboxetine in patients with severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Increased neurogenesis and brain‐derived neurotrophic factor in neurokinin‐1 receptor gene knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Treatment of major depression with steroid suppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The neuropsychopharmacological potential of neuroactive steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Sustained response to open-label venlafaxine in drug-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Safety profile of sustained-release bupropion in depression: results of three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Neurokinin(1) receptor antagonists as potential antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

The antidopaminergic action of S-20098 is mediated by benzodiazepine/GABA(A) receptors in the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Safety of Hypericum extract in mildly to moderately depressed outpatients: a review based on data from three randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Comparison of St John's wort and imipramine for treating depression: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Dehydroepiandrosterone (DHEA) treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Antiglucocorticoid treatment of depression: double-blind ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Herbal remedies in psychiatric practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Dopamine transporter-dependent induction of C-Fos in HEK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Recent advances in melatonin receptor ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Tranylcypromine versus imipramine in anergic bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Treatment of imipramine-resistant recurrent depression, IV: A double- blind crossover study of tranylcypromine for anergic bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Ketoconazole administration in hypercortisolemic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15622970601003973

10.1080/15622970601003973

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference